Intellia Therapeutics Announces Third Quarter 2022 Financial ...

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress ; $848.7 million as of September 30, ...

Intellia Therapeutics Announces Third Quarter 2022 - GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress ; Total other (expense) income, net ...

Intellia Therapeutics Announces Third Quarter 2024 Financial ...

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ; $944.7 million as of September 30, ...

Press Releases - Intellia Therapeutics - investor relations

... therapies leveraging CRISPR-based ... Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress.

Intellia Therapeutics Announces Third Quarter 2023 Financial ...

Net Loss: The Company's net loss was $122.2 million for the third quarter of 2023, compared to $113.2 million during the third quarter of 2022.

Intellia Therapeutics Announces Third Quarter 2022 Financial ...

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress. Start Trading Futures.

Press Releases - Intellia Therapeutics - investor relations

Third quarter 2024 financial results – November 7 , at 8 a.m. ET New clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of ...

Intellia Therapeutics Announces Third Quarter 2023 - GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress · U.S. callers should dial 1-833-316- ...

Biotech2k on X: "Intellia Therapeutics Announces Third Quarter ...

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress https://t.co/EWwErznYUx via @YahooFinance.

Regeneron Reports Third Quarter 2022 Financial and Operating ...

Total revenues decreased 15% to $2.936 billion in the third quarter of 2022, compared to $3.453 billion in the third quarter of 2021.

Tenax Therapeutics Reports Third Quarter 2024 Financial Results ...

Research and Development expenses for the third quarter of 2024 were $3.1 million, compared to $1.1 million for the third quarter of 2023. The ...

Intellia Therapeutics Third Quarter 2022 Earnings: Revenues Beat ...

Intellia Therapeutics ( NASDAQ:NTLA ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.3m (up 84% from...

NTLA SEC Filings - Intellia Therapeutics, Inc.- Annual Report, Proxy ...

Press Releases and Other. 2024-11-07, EX-99.1. Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress.

Intra-Cellular Therapies Reports Third Quarter 2022 Financial ...

Total revenues were $71.9 million for the third quarter of 2022, compared to $22.2 million for the third quarter of 2021. Net product revenues of CAPLYTA were ...

Press Releases - CRISPR Therapeutics

... 2022 Annual Meeting. Nov 01, 2022. CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results. Oct 27, 2022. CRISPR ...

Intellia Therapeutics - Revolutionize the course of medicine

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based ...

SpringWorks Therapeutics Reports Third Quarter 2024 Financial ...

Continued strong commercial execution of the OGSIVEO launch, with net product revenue of $49.3 million in the third quarter of 2024, ...

Zevra Therapeutics Reports Third Quarter 2024 Financial Results ...

Zevra Therapeutics reported Q3 2024 financial results, highlighting the FDA approval of MIPLYFFA™ for Niemann-Pick disease type C treatment.

Intellia Therapeutics Announces Third Quarter 2024 Financial ...

(NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported ...

Intellia Therapeutics to Hold Conference Call to Discuss Third ...

(NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based ...